Loading...
XSTO
ISOFOL
Market cap25mUSD
Jul 10, Last price  
0.91SEK
1D
2.72%
1Q
-49.13%
IPO
-96.60%
Name

Isofol Medical AB (publ)

Chart & Performance

D1W1MN
XSTO:ISOFOL chart
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
23.33%
Rev. gr., 5y
-11.85%
Revenues
0k
-100.00%
0187,000508,000227,0000037,119,00022,407,00012,797,000721,0000
Net income
-43m
L+17.31%
-10,601,308-40,689,000-64,018,000-72,035,000-83,125,000-157,231,000-188,992,000-196,884,000-155,943,000-37,071,000-43,488,000
CFO
-42m
L-20.08%
0-36,767,000-56,902,000-61,943,000-92,458,000-147,208,000-160,270,000-188,429,000-190,975,000-52,536,000-41,986,000
Earnings
Aug 19, 2025

Profile

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
IPO date
Apr 04, 2017
Employees
3
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
721
-94.37%
12,797
-42.89%
Cost of revenue
38,734
35,136
178,504
Unusual Expense (Income)
NOPBT
(38,734)
(34,415)
(165,707)
NOPBT Margin
Operating Taxes
(3,812)
Tax Rate
NOPAT
(38,734)
(34,415)
(161,895)
Net income
(43,488)
17.31%
(37,071)
-76.23%
(155,943)
-20.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
23
BB yield
-0.02%
Debt
Debt current
1,543
Long-term debt
6,353
Deferred revenue
Other long-term liabilities
648
911
846
Net debt
(96,157)
(138,148)
(182,737)
Cash flow
Cash from operating activities
(41,986)
(52,536)
(190,975)
CAPEX
Cash from investing activities
101
Cash from financing activities
(1,681)
FCF
(38,731)
(30,404)
(164,163)
Balance
Cash
96,157
138,148
190,583
Long term investments
50
Excess cash
96,157
138,112
189,993
Stockholders' equity
(1,140,332)
(1,096,844)
(1,059,129)
Invested Capital
1,218,925
1,219,188
1,222,401
ROIC
ROCE
EV
Common stock shares outstanding
161,067
161,515
161,515
Price
2.22
204.11%
0.73
-1.35%
0.74
-91.99%
Market cap
357,568
203.26%
117,906
-1.35%
119,521
-89.70%
EV
261,411
(20,242)
(63,216)
EBITDA
(38,734)
(34,378)
(164,065)
EV/EBITDA
0.59
0.39
Interest
44
Interest/NOPBT